Celularity
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
170 Park Ave, Florham Park, New Jersey, ...Phone Number
(908) 768-2170Website
www.celularity.comRevenue
$26.6 MillionStock Symbol
CELUIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About Celularity
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy.Explore more
Celularity Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Celularity your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Celularity has new funding data
Earning: See what the market has to say on Celularity recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Celularity
Check if Celularity has recently received funding, and reach out quickly before it becomes old news!
Celularity, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Celularity is spiking on competitors!
Product Launch: Get notified when Celularity launches new products
Click to see if Celularity had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Celularity
Compare insights from companies similar to Celularity, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Celularity is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Celularity is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Celularity.
Celularity financials insights
Gather financial insights about Celularity, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Unspecified
$250M
2025
Multiple Rounds
$21.8M
2026
Other Financing Round
$13.3M
Celularity Tech Stack
A closer look at the technologies used by Celularity
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Person-Based
Open Position
Seeking Replacement
Promotion
Executive Move
Executive Moves, Promotion
Celularity News & Media
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and Lifebank Appointment supports Celularity’s focus on longevity, regenerative medicine and preservation of human performance by advancing commercialization of cenplacel-L and LifebankCelularity Receives Nasdaq Notice Regarding Form 10-Q
FLORHAM PARK, N.J., May 29, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a longevity-focused regenerative and cellular medicine company, today announced that it received a notification letter on May 27, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that, as a result of the Company’s delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2026, the Company is not in complianceCelularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation
Company advances focused strategy, strengthens balance sheet and positions business for long-term growth Company advances focused strategy, strengthens balance sheet and positions business for long-term growth
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Celularity
Sign Up For FreeTo access detailed company insights
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segme... Read More
